Open Label Randomized Bioequivalence Study to Evaluate the PK and Safety Profile of Bevacizumab Biosimilar (BEVZ92) With FOLFOX or FOLFIRI vs Bevacizumab (AVASTIN) With FOLFOX or FOLFIRI in First-line Treatment for mCRC Patients.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Pharmacokinetics
- Sponsors mAbxience
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 22 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2017.
- 22 Dec 2016 Status changed from completed to active, no longer recruiting.